Zoliflodacin shows promise as single-dose treatment for gonorrhea
A Phase III trial has demonstrated that zoliflodacin – a single-dose oral antibiotic – is highly effective against drug‐resistant gonorrhea, offering an innovative solution to a mounting public health threat. The encouraging results suggest a potential game‐changer in the fight against antibiotic-resistant infections.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Apixaban linked to lower bleeding than rivaroxaban in head‑to‑head study / 2 months
PAXG regimen shows superior event‐free survival in early pancreatic cancer / 6 months
Therapeutic HPV vaccine slows throat tumors in preclinical tests / 3 months
Gene‑editing trials explore one‑time fix for high cholesterol / 3 months
Bayer’s Asundexian Reduces Stroke Risk by 26% in Phase 3 Trial / 3 months
Eikon Therapeutics raises $381M IPO for cancer drug advancement / 3 months
Aktis Oncology IPO boosts radiopharmaceutical pipeline / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Adolescent Health, Pfizer, Medicaid, Animal Health and look for the RSS link.
StackHealth Time Machine